TSBX — Turnstone Biologics Balance Sheet
0.000.00%
- $8.21m
- -$13.63m
Annual balance sheet for Turnstone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 161 | 82.1 | 94.8 | 28.9 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 6.71 | 8.73 | 0.194 | 0 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 177 | 98 | 103 | 34.2 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 9.37 | 14.4 | 9.12 | 5.11 |
| Other Long Term Assets | ||||
| Total Assets | 187 | 115 | 113 | 40.1 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | 55 | 34.8 | 12 | 8.2 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 97.3 | 44.5 | 14.1 | 8.67 |
| Redeemable Preferred Stock | ||||
| Non Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | 89.9 | 70.5 | 98.7 | 31.5 |
| Total Liabilities & Shareholders' Equity | 187 | 115 | 113 | 40.1 |
| Total Common Shares Outstanding |